Uncategorized

Oncomatryx’s OMTX705 Selected for New Combination Research Collaboration Between InxMed and HanchorBio

by

The preclinical agreement highlights growing external interest in the combination potential of Oncomatryx’s FAP-targeted ADC, licensed to InxMed for Greater China, Taiwan, South Korea and Southeast Asia ZAMUDIO (Bizkaia), 27th July 2026 – Oncomatryx’s OMTX705, an antibody-drug conjugate directed against the tumor microenvironment, is among the assets selected by Taiwan-listed HanchorBio for a new combination … Read more

Kutxa Fundazioa, the Basque Government, and the Spanish Government are driving Oncomatryx’s transformation into a biopharmaceutical company

by

The Spanish Government is contributing 24.3 million euros through the Ministry of Science, Innovation, and Universities, reinforcing its commitment to technological innovation for health. Kutxa Fundazioa leads the Basque investment with 15 million euros, alongside a 10.5 million euro contribution from the Basque Government and Ekarpen and 2 million euros from BBK, bringing the total … Read more